Promore Pharma
19.11.2021 13:31:49 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 19, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Promore Pharma AB (publ) publishes its interim report for the third quarter 2021 on 23 November 2021.
The next day, 24 November, the company will host a webcast telephone conference at 09.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and upcoming activities. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet, or telephone.
The number of attendees is limited, please register for the conference in advance on the following link:
https://attendee.gotowebinar.com/register/3513796589233231628
The conference call will be recorded and made available on the company´s website after the call, and on
Västra Hamnen Corporate Finance Youtube channel.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
Invitation to Conference Call regarding Promore Pharma's Interim Report for the Third Quarter 2021
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/673758/Invitation-to-Conference-Call-Regarding-Promore-Pharmas-Interim-Report-for-the-Third-Quarter-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
LiberNovo 2026 Triple Launch: SE, Pro, and Maxis Introduce Dynamic Ergonomics for Every Body Type Across Europe18.5.2026 19:00:00 CEST | Press release
LONDON, GB / ACCESS Newswire / May 18, 2026 / LiberNovo, the premium ergonomic chair brand pioneering movement-based seating, today confirmed the full details of its 2026 product expansion for the European market. Three new lines-the Omni SE, Omni Pro, and the all-new Maxis series-will be available to customers across the UK and EU starting June 16, with pre-orders now open. Across Europe, the shift toward hybrid and remote work has turned the home office into a permanent fixture. Yet the chair at the centre of that setup is often the last thing to be upgraded. Most ergonomic seating still operates on a decades-old premise: find the correct posture, lock it in, stay put. LiberNovo rejects that model entirely. Its Dynamic Ergonomics platform is built around continuous adaptation-chairs that respond to how users actually move through their day, rather than forcing them into a fixed position. With three distinct product lines, that approach now reaches users of every build and budget. Omn
Europe's Healthcare IT Market Enters the 2027 Readiness Cycle as Black Book Names 26 Top Client-Rated Vendors During HIMSS26 Week in Copenhagen18.5.2026 18:00:00 CEST | Press release
Category-specific honors identify client-rated leaders in data-ready EHRs, interoperability, enterprise imaging, cloud, cybersecurity, AI, advisory, analytics, clinical decision support and digital health infrastructure COPENHAGEN, DK / ACCESS Newswire / May 18, 2026 / Black Book Research today announced its 2026 European Healthcare IT Client Satisfaction Honors, recognizing 26 healthcare technology vendors and platforms whose strongest client-facing performance aligns with the next phase of European digital health: trusted data, cross-border interoperability, AI accountability, cybersecurity resilience, cloud modernization, enterprise imaging liquidity, analytics readiness and clinical workflow transformation. The announcement is timed to HIMSS26 Europe, taking place 19-21 May 2026 at the Bella Center in Copenhagen, Denmark, where healthcare leaders, innovators and policymakers are convening around digital maturity, AI, interoperability, cybersecurity and health system transformation.
Tyson Fury, The Gypsy King, Joins Datavault AI as International Spokesperson to Champion Athlete Data Monetization18.5.2026 14:37:00 CEST | Press release
Forbes' Third Highest-Paid Athlete in the World Brings Global Platform to Datavault AI's Sports Illustrated Exchange and NIL Monetization Initiative PHILADELPHIA, PA / ACCESS Newswire / May 18, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA') tokenization technologies, today announced that two-time world heavyweight champion Tyson Fury has signed on as International Spokesperson for Datavault AI a deal brokered by Nick Hunter of P11. Ranked No. 3 on Forbes' 2025 list of the world's highest-paid athletes with $146 million in estimated earnings (Forbes 2025), Fury brings global star power, and a uniquely personal understanding of what it means to own, protect, and capitalize on a name, to Datavault AI's mission of empowering individuals and organizations to monetize their data and digital assets. Known worldwide as "The Gypsy King," his appointment immediately precede
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform15.5.2026 22:55:00 CEST | Press release
NESHER, ISRAEL / ACCESS Newswire / May 15, 2026 / Tabor Electronics today announced the commercial release of its Anti-Drone Test and Evaluation (T&E) solution, introducing a software-defined approach to validating counter-unmanned aircraft systems (C-UAS). Built on the company's Proteus™ Software Defined Radio (SDR) platform, the solution enables defense and security organizations to test and deploy counter-drone technologies in rapidly changing threat environments. As low-cost drones proliferate and communication protocols evolve, traditional hardware-bound test environments are struggling to keep pace. Tabor's platform replaces these constraints with a programmable framework that allows engineering teams to emulate and validate real-world RF scenarios in controlled lab environments-reducing reliance on extended field testing while accelerating development timelines. Originally developed in collaboration with leading anti-drone technology companies, the solution has already been prov
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program14.5.2026 21:05:00 CEST | Press release
Highlights: WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutions Combination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmacies Proposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordination Proposed transaction valued at approximately $15 million Strategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providers TAMPA, FL / ACCESS Newswire / May 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it has executed a non-binding letter of intent ("LOI") to acquire WellCare Today. The proposed transaction structure includes a structured cash payment of $3 million,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom